PEGylation alleviates the non-specific toxicities of Alpha-Momorcharin and preserves its antitumor efficacy in vivo

Drug Delivery

Volumn 23, Issue 1, 2016, Pages 95-100

  Deng, Nian Hua ^a,b   Wang, Ling ^b   He, Qian Chuan ^c   Zheng, Jue Cun ^b   Meng, Yao ^b   Meng, Yan Fa ^a   Zhang, Chong Jie ^a   Shen, Fu Bing ^b  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU MEDICAL COLLEGE   (China)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

anti tumor activity; PEGylation; pharmacokinetics; MMC; MMC PEG

Indexed keywords

ALPHA MOMORCHARIN; ANTINEOPLASTIC AGENT; RIBOSOME INACTIVATING PROTEIN; UNCLASSIFIED DRUG; MACROGOL DERIVATIVE; MMC PROTEIN, MOMORDICA CHARANTIA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CARCINOMA; CANCER GRAFT; CANCER INHIBITION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG METABOLISM; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOMORDICA CHARANTIA; MOUSE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR VOLUME; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CHEMISTRY; DOSE RESPONSE; HALF LIFE TIME; MAMMARY NEOPLASMS, EXPERIMENTAL; MEDICINAL CHEMISTRY; METABOLISM; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RIBOSOME INACTIVATING PROTEINS;

EID: 84954315292     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.905652     Document Type: Article

References (18)

1. Alley MC, Hollingshead MG, Dykes DJ, Waud WR. (2004). Human tumor xenograft models in NCI drug development. In: Teicher BA, Andrews PA, eds. Anticancer drug development guide: preclinical screening, clinical trials, and approval. 2nd ed. Totowa (NJ): Humana Press, Inc., 125-52.
2. Bailon P, Palleroni A, Schaffer CA, et al. (2001). Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12:195-202.
3. Basch E, Gabardi S, Ulbricht C. (2003). Bitter melon (Momordica charantia): A review of efficacy and safety. Am J Health Syst Pharm 60:356-9.
4. Bian X, Shen F, Chen Y, et al. (2010). PEGylation of alphamomorcharin: synthesis and characterization of novel anti-tumor conjugates with therapeutic potential. Biotechnol Lett 32:883-90.
5. Clark R, Olson K, Fuh G, et al. (1996). Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 271: 21969-77.
6. He XH, Shaw PC, Tam SC. (1999). Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. Life Sci 65:355-68.
7. Kaur I, Yadav SK, Hariprasad G, et al. (2012). Balsamin, a novel ribosome-inactivating protein from the seeds of Balsam apple Momordica balsamina. Amino Acids 43:973-81.
8. Leung KC, Meng ZQ, Ho WK. (1997). Antigenic determination fragments of alpha-momorcharin. Biochim Biophys Acta 1336: 419-24.
9. Li M, Chen Y, Liu Z, et al. (2009). Anti-tumor activity and immunological modification of ribosome-inactivating protein (RIP) from Momordica charantia by covalent attachment of polyethylene glycol. Acta Biochim Biophys Sin (Shanghai) 41:792-9.
10. Meng Y, Liu B, Lei N, et al. (2012). Alpha-momorcharin possessing high immunogenicity, immunotoxicity and hepatotoxicity in SD rats. J Ethnopharmacol 139:590-8.
11. Ng TB, Liu WK, Sze SF, Yeung HW. (1994). Action of alphamomorcharin, a ribosome inactivating protein, on cultured tumor cell lines. Gen Pharmacol 25:75-7.
12. Niv-Spector L, Shpilman M, Boisclair Y, Gertler A. (2012). Largescale preparation and characterization of non-pegylated and pegylated superactive ovine leptin antagonist. Protein Expr Purif 81: 186-92.
13. Park SW, Lawrence CB, Linden JC, Vivanco JM. (2002). Isolation and characterization of a novel ribosome-inactivating protein from root cultures of pokeweed and its mechanism of secretion from roots. Plant Physiol 130:164-78.
14. Park SW, Prithiviraj B, Vepachedu R, Vivanco JM. (2006). Isolation and purification of ribosome-inactivating proteins. Methods Mol Biol 318: 335-47.
15. Wang YX, Jacob J, Wingfield PT, et al. (2000). Anti-HIV and anti-tumor protein MAP30, a 30 kDa single-strand type-I RIP, shares similar secondary structure and beta-sheet topology with the A chain of ricin, a type-II RIP. Protein Sci 9:138-44.
16. Wang JH, Tam SC, Huang H, et al. (2004). Site-directed PEGylation of trichosanthin retained its anti-HIV activity with reduced potency in vitro. Biochem Biophys Res Commun 317: 965-71.
17. Zheng JC, Lei N, He QC, et al. (2012). PEGylation is effective in reducing immunogenicity, immunotoxicity, and hepatotoxicity of alpha-momorcharin in vivo. Immunopharmacol Immunotoxicol 34: 866-73.
18. Zhu G, Huang Q, Qian M, Tang Y. (2001). Crystal structure of alphamomorcharin in 80% acetonitrile-water mixture. Biochim Biophys Acta 1548:152-8.